Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 ADORA1 6件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00045 Adenosine 3件: 13, 58, 65
2 ADORA1 6件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00227 Aminophylline 1件: 63
3 ADORA1 6件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00371 Theophylline 2件: 236, 299
4 ADORA1 6件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
5 ADORA1 6件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
6 ADORA1 6件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01712 Theophylline 2件: 236, 299
7 ADORA1 6件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02017 Theophylline 2件: 236, 299
8 ADORA1 6件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02769 Adenosine phosphate 1件: 46
9 ADORA1 6件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D05429 Aminophylline 1件: 63
10 ADORA1 6件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D06103 Theophylline 2件: 236, 299
11 ADORA1 6件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D06104 Theophylline 2件: 236, 299
12 ADORA3 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00045 Adenosine 3件: 13, 58, 65
13 ADORA3 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02769 Adenosine phosphate 1件: 46
14 ADORA3 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10971 Piclidenoson 1件: 46
15 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine 1件: 22
16 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine 3件: 46, 70, 96
17 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine 1件: 11
18 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol 5件: 6, 57, 86, 113, 210
19 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine 2件: 2, 8
20 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine 1件: 17
21 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine 1件: 22
22 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin 2件: 57, 67
23 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin 1件: 6
24 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone 2件: 28, 127
25 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine 3件: 118, 280, 288
26 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine 3件: 46, 70, 96
27 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa 5件: 5, 6, 17, 169, 170
28 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine 3件: 6, 17, 58
29 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine 3件: 46, 70, 96
30 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate 2件: 6, 206
31 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin 1件: 6
32 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone 2件: 28, 127
33 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol 5件: 6, 57, 86, 113, 210
34 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine 1件: 22
35 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine 1件: 17
36 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine 1件: 17
37 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine 2件: 2, 8
38 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin 2件: 57, 67
39 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil 1件: 85
40 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine 3件: 118, 280, 288
41 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine 3件: 6, 17, 58
42 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine 1件: 22
43 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine 1件: 17
44 ADRA1D 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin 1件: 6
45 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine 1件: 22
46 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine 3件: 46, 70, 96
47 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine 1件: 11
48 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol 5件: 6, 57, 86, 113, 210
49 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine 2件: 2, 8
50 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine 1件: 17
51 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine 1件: 22
52 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin 2件: 57, 67
53 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin 1件: 6
54 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone 2件: 28, 127
55 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine 3件: 118, 280, 288
56 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine 3件: 46, 70, 96
57 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa 5件: 5, 6, 17, 169, 170
58 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine 3件: 6, 17, 58
59 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine 3件: 46, 70, 96
60 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate 2件: 6, 206
61 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin 1件: 6
62 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone 2件: 28, 127
63 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol 5件: 6, 57, 86, 113, 210
64 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine 1件: 22
65 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine 1件: 17
66 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine 1件: 17
67 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine 2件: 2, 8
68 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin 2件: 57, 67
69 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil 1件: 85
70 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine 3件: 118, 280, 288
71 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine 3件: 6, 17, 58
72 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine 1件: 22
73 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine 1件: 17
74 ADRA1B 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin 1件: 6
75 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine 1件: 22
76 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine 3件: 46, 70, 96
77 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine 1件: 11
78 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol 5件: 6, 57, 86, 113, 210
79 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine 2件: 2, 8
80 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine 1件: 17
81 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine 1件: 22
82 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin 2件: 57, 67
83 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin 1件: 6
84 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone 2件: 28, 127
85 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine 3件: 118, 280, 288
86 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine 3件: 46, 70, 96
87 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa 5件: 5, 6, 17, 169, 170
88 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine 3件: 6, 17, 58
89 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01692 Alfuzosin 1件: 13
90 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01965 Silodosin 2件: 6, 13
91 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine 3件: 46, 70, 96
92 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate 2件: 6, 206
93 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin 1件: 6
94 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone 2件: 28, 127
95 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol 5件: 6, 57, 86, 113, 210
96 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine 1件: 22
97 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine 1件: 17
98 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine 1件: 17
99 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine 2件: 2, 8
100 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07124 Alfuzosin 1件: 13
101 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin 2件: 57, 67
102 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil 1件: 85
103 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine 3件: 118, 280, 288
104 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine 3件: 6, 17, 58
105 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine 1件: 22
106 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine 1件: 17
107 ADRA1A 4件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin 1件: 6
108 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine 1件: 22
109 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine 3件: 46, 70, 96
110 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00124 Ephedrine 1件: 11
111 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00270 Chlorpromazine 1件: 254
112 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine 4件: 6, 65, 70, 78
113 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine 1件: 6
114 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00405 Methyldopa 1件: 323
115 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00485 Pseudoephedrine 1件: 17
116 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
117 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00560 Pimozide 1件: 2
118 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00604 Clonidine 4件: 6, 65, 70, 78
119 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00606 Guanfacine 1件: 193
120 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00680 Methylergometrine 3件: 118, 280, 288
121 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00776 Tizanidine 1件: 13
122 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00789 Chlorpromazine 1件: 254
123 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine 3件: 46, 70, 96
124 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01008 Apraclonidine 1件: 11
125 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
126 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa 5件: 5, 6, 17, 169, 170
127 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02076 Brimonidine 2件: 13, 90
128 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine 3件: 46, 70, 96
129 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate 2件: 6, 206
130 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin 1件: 6
131 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D03274 Chlorpromazine 1件: 254
132 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04034 Chlorpromazine 1件: 254
133 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz 2件: 2, 13
134 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05206 Norepinephrine 1件: 22
135 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05648 Pseudoephedrine 1件: 17
136 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05649 Pseudoephedrine 1件: 17
137 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07461 Apraclonidine 1件: 11
138 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine 2件: 13, 90
139 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08031 Guanfacine 1件: 193
140 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08205 Methyldopa 1件: 323
141 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08207 Methylergometrine 3件: 118, 280, 288
142 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine 1件: 17
143 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08482 Rilmenidine 1件: 8
144 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine 1件: 13
145 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine 1件: 6
146 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine 1件: 22
147 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine 3件: 46, 70, 96
148 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00124 Ephedrine 1件: 11
149 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00270 Chlorpromazine 1件: 254
150 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine 4件: 6, 65, 70, 78
151 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine 1件: 6
152 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00405 Methyldopa 1件: 323
153 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00485 Pseudoephedrine 1件: 17
154 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
155 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00604 Clonidine 4件: 6, 65, 70, 78
156 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00680 Methylergometrine 3件: 118, 280, 288
157 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00776 Tizanidine 1件: 13
158 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00789 Chlorpromazine 1件: 254
159 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine 3件: 46, 70, 96
160 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01008 Apraclonidine 1件: 11
161 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
162 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa 5件: 5, 6, 17, 169, 170
163 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02076 Brimonidine 2件: 13, 90
164 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine 3件: 46, 70, 96
165 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate 2件: 6, 206
166 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin 1件: 6
167 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D03274 Chlorpromazine 1件: 254
168 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04034 Chlorpromazine 1件: 254
169 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz 2件: 2, 13
170 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05206 Norepinephrine 1件: 22
171 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05648 Pseudoephedrine 1件: 17
172 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05649 Pseudoephedrine 1件: 17
173 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07461 Apraclonidine 1件: 11
174 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine 2件: 13, 90
175 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08205 Methyldopa 1件: 323
176 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08207 Methylergometrine 3件: 118, 280, 288
177 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine 1件: 17
178 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08482 Rilmenidine 1件: 8
179 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine 1件: 13
180 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine 1件: 6
181 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine 1件: 22
182 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine 3件: 46, 70, 96
183 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00124 Ephedrine 1件: 11
184 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00270 Chlorpromazine 1件: 254
185 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine 4件: 6, 65, 70, 78
186 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine 1件: 6
187 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00405 Methyldopa 1件: 323
188 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00485 Pseudoephedrine 1件: 17
189 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
190 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00604 Clonidine 4件: 6, 65, 70, 78
191 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00680 Methylergometrine 3件: 118, 280, 288
192 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00776 Tizanidine 1件: 13
193 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00789 Chlorpromazine 1件: 254
194 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine 3件: 46, 70, 96
195 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01008 Apraclonidine 1件: 11
196 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
197 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa 5件: 5, 6, 17, 169, 170
198 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02076 Brimonidine 2件: 13, 90
199 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine 3件: 46, 70, 96
200 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate 2件: 6, 206
201 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin 1件: 6
202 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D03274 Chlorpromazine 1件: 254
203 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04034 Chlorpromazine 1件: 254
204 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz 2件: 2, 13
205 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05206 Norepinephrine 1件: 22
206 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05648 Pseudoephedrine 1件: 17
207 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05649 Pseudoephedrine 1件: 17
208 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07461 Apraclonidine 1件: 11
209 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine 2件: 13, 90
210 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08205 Methyldopa 1件: 323
211 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08207 Methylergometrine 3件: 118, 280, 288
212 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine 1件: 17
213 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08482 Rilmenidine 1件: 8
214 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine 1件: 13
215 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine 1件: 6
216 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00076 Norepinephrine 1件: 22
217 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00095 Epinephrine 3件: 46, 70, 96
218 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00124 Ephedrine 1件: 11
219 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00235 Atenolol 1件: 167
220 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00255 Carvedilol 5件: 6, 57, 86, 113, 210
221 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00378 Timolol 2件: 157, 227
222 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00432 Nadolol 1件: 6
223 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00483 Propranolol 7件: 6, 158, 167, 215, 227, 278, 296
224 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00485 Pseudoephedrine 1件: 17
225 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00601 Metoprolol 6件: 17, 57, 58, 113, 193, 226
226 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00603 Timolol 2件: 157, 227
227 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00632 Dobutamine 3件: 57, 58, 215
228 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00634 Bisoprolol 3件: 67, 86, 113
229 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00636 Amiodarone 2件: 28, 127
230 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00644 Esmolol 1件: 58
231 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00996 Epinephrine 3件: 46, 70, 96
232 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D01277 Droxidopa 5件: 5, 6, 17, 169, 170
233 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02149 Epinephrine 3件: 46, 70, 96
234 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02342 Bisoprolol 3件: 67, 86, 113
235 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02349 Dipivefrin 1件: 6
236 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02358 Metoprolol 6件: 17, 57, 58, 113, 193, 226
237 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02910 Amiodarone 2件: 28, 127
238 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03415 Carvedilol 5件: 6, 57, 86, 113, 210
239 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03879 Dobutamine 3件: 57, 58, 215
240 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03880 Dobutamine 3件: 57, 58, 215
241 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03881 Dobutamine 3件: 57, 58, 215
242 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05011 Metoprolol 6件: 17, 57, 58, 113, 193, 226
243 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05127 Nebivolol 4件: 17, 85, 113, 167
244 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05206 Norepinephrine 1件: 22
245 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05648 Pseudoephedrine 1件: 17
246 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05649 Pseudoephedrine 1件: 17
247 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D07660 Celiprolol 1件: 168
248 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D07916 Esmolol 1件: 58
249 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08443 Propranolol 7件: 6, 158, 167, 215, 227, 278, 296
250 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08449 Pseudoephedrine 1件: 17
251 ADRB1 8件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08600 Timolol 2件: 157, 227
252 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00076 Norepinephrine 1件: 22
253 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine 3件: 46, 70, 96
254 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00124 Ephedrine 1件: 11
255 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00255 Carvedilol 5件: 6, 57, 86, 113, 210
256 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00378 Timolol 2件: 157, 227
257 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00432 Nadolol 1件: 6
258 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00483 Propranolol 7件: 6, 158, 167, 215, 227, 278, 296
259 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00485 Pseudoephedrine 1件: 17
260 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00603 Timolol 2件: 157, 227
261 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00687 Salmeterol 1件: 299
262 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00688 Terbutaline 1件: 118
263 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00996 Epinephrine 3件: 46, 70, 96
264 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa 5件: 5, 6, 17, 169, 170
265 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01373 Formoterol 3件: 85, 228, 299
266 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02147 Salbutamol 14件: 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299
267 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02149 Epinephrine 3件: 46, 70, 96
268 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02151 Tulobuterol 1件: 6
269 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin 1件: 6
270 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D03415 Carvedilol 5件: 6, 57, 86, 113, 210
271 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05206 Norepinephrine 1件: 22
272 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05277 Formoterol 3件: 85, 228, 299
273 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05648 Pseudoephedrine 1件: 17
274 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05649 Pseudoephedrine 1件: 17
275 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05792 Salmeterol 1件: 299
276 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07713 Clenbuterol 5件: 1, 2, 6, 13, 256
277 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07990 Formoterol 3件: 85, 228, 299
278 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08092 Isoxsuprine 1件: 13
279 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08124 Levosalbutamol 1件: 49
280 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol 7件: 6, 158, 167, 215, 227, 278, 296
281 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08449 Pseudoephedrine 1件: 17
282 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08570 Terbutaline 1件: 118
283 ADRB2 6件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08600 Timolol 2件: 157, 227
284 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00076 Norepinephrine 1件: 22
285 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine 3件: 46, 70, 96
286 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00124 Ephedrine 1件: 11
287 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00483 Propranolol 7件: 6, 158, 167, 215, 227, 278, 296
288 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00485 Pseudoephedrine 1件: 17
289 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00996 Epinephrine 3件: 46, 70, 96
290 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa 5件: 5, 6, 17, 169, 170
291 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02149 Epinephrine 3件: 46, 70, 96
292 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin 1件: 6
293 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05206 Norepinephrine 1件: 22
294 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05648 Pseudoephedrine 1件: 17
295 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05649 Pseudoephedrine 1件: 17
296 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol 7件: 6, 158, 167, 215, 227, 278, 296
297 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08449 Pseudoephedrine 1件: 17
298 ADRB3 7件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D09535 Mirabegron 4件: 6, 13, 53, 226
299 AGTR1 11件: cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00150 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
300 AGTR1 11件: cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00357 Losartan 18件: 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
301 AGTR1 11件: cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00400 Valsartan 7件: 57, 58, 66, 75, 218, 222, 224
302 AGTR1 11件: cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00522 Candesartan cilexetil 1件: 67
303 AGTR1 11件: cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00522 Candesartan 2件: 58, 67
304 AGTR1 11件: cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00523 Irbesartan 4件: 66, 167, 168, 222
305 AGTR1 11件: cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00626 Candesartan cilexetil 1件: 67
306 AGTR1 11件: cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00627 Telmisartan 2件: 66, 67
307 AGTR1 11件: cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D02014 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
308 AGTR1 11件: cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D08146 Losartan 18件: 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
309 AGTR1 11件: cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D11776 Sparsentan 3件: 66, 218, 222
310 EDNRA 5件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D01227 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
311 EDNRA 5件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07077 Ambrisentan 7件: 51, 84, 85, 86, 88, 210, 211
312 EDNRA 5件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07171 Sitaxentan 1件: 86
313 EDNRA 5件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07538 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
314 EDNRA 5件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07741 Zibotentan 1件: 51
315 EDNRA 5件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D10135 Macitentan 5件: 51, 85, 86, 88, 210
316 EDNRA 5件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D11776 Sparsentan 3件: 66, 218, 222
317 EDNRB 5件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D01227 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
318 EDNRB 5件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D07538 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
319 EDNRB 5件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D10135 Macitentan 5件: 51, 85, 86, 88, 210
320 GUCY1A2 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D00517 Amyl Nitrite 1件: 58
321 GUCY1A2 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D09572 Riociguat 6件: 51, 84, 86, 88, 225, 299
322 GUCY1A1 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D00517 Amyl Nitrite 1件: 58
323 GUCY1A1 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D09572 Riociguat 6件: 51, 84, 86, 88, 225, 299
324 GUCY1B1 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D00517 Amyl Nitrite 1件: 58
325 GUCY1B1 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D09572 Riociguat 6件: 51, 84, 86, 88, 225, 299
326 INSR 18件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Diabetic cardiomyopathy D00085 Insulin human 2件: 96, 156
327 INSR 18件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Diabetic cardiomyopathy D03230 Insulin human 2件: 96, 156
328 INSR 18件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Diabetic cardiomyopathy D03250 Insulin glargine 1件: 299
329 INSR 18件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Diabetic cardiomyopathy D04539 Insulin detemir 1件: 299
330 KCNJ8 1件: cGMP-PKG signaling pathway D00636 Amiodarone 2件: 28, 127
331 KCNJ8 1件: cGMP-PKG signaling pathway D02910 Amiodarone 2件: 28, 127
332 MYH7 5件: cGMP-PKG signaling pathway, Thyroid hormone signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Viral myocarditis D12265 Mavacamten 1件: 58
333 ATP1A1 11件: cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00297 Digitoxin 1件: 299
334 ATP1A1 11件: cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
335 ATP1A2 11件: cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00297 Digitoxin 1件: 299
336 ATP1A2 11件: cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
337 ATP1A3 11件: cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00297 Digitoxin 1件: 299
338 ATP1A3 11件: cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
339 ATP1A4 11件: cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00297 Digitoxin 1件: 299
340 ATP1A4 11件: cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
341 NPR1 8件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Thermogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion D04051 Erythrityl tetranitrate 1件: 46
342 NPR1 8件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Thermogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion D05147 Nesiritide 2件: 46, 58
343 NPR2 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Oxytocin signaling pathway D04051 Erythrityl tetranitrate 1件: 46
344 NPR2 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Oxytocin signaling pathway D11190 Vosoritide 1件: 276
345 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00729 Loperamide 2件: 13, 97
346 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00843 Nalbuphine 1件: 85
347 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D01340 Naloxone 2件: 6, 226
348 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02095 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
349 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D03783 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
350 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05111 Nalmefene 1件: 6
351 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05113 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
352 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05312 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
353 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05462 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
354 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D07113 Loperamide 2件: 13, 97
355 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08144 Loperamide 2件: 13, 97
356 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08246 Nalbuphine 1件: 85
357 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08249 Naloxone 2件: 6, 226
358 PDE2A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D00227 Aminophylline 1件: 63
359 PDE2A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D00371 Theophylline 2件: 236, 299
360 PDE2A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
361 PDE2A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D00718 Flavoxate 1件: 226
362 PDE2A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
363 PDE2A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D01712 Theophylline 2件: 236, 299
364 PDE2A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D02017 Theophylline 2件: 236, 299
365 PDE2A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D05429 Aminophylline 1件: 63
366 PDE2A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D06103 Theophylline 2件: 236, 299
367 PDE2A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D06104 Theophylline 2件: 236, 299
368 PDE2A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D07546 Bucladesine 1件: 246
369 PDE2A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction D07961 Flavoxate 1件: 226
370 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D00227 Aminophylline 1件: 63
371 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D00371 Theophylline 2件: 236, 299
372 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D00417 Milrinone 1件: 294
373 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
374 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D00718 Flavoxate 1件: 226
375 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D01385 Ibudilast 2件: 2, 13
376 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
377 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D01712 Theophylline 2件: 236, 299
378 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D01896 Cilostazol 3件: 51, 70, 124
379 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D02017 Theophylline 2件: 236, 299
380 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D02085 Milrinone 1件: 294
381 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D04720 Levosimendan 1件: 2
382 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D05429 Aminophylline 1件: 63
383 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D06103 Theophylline 2件: 236, 299
384 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D06104 Theophylline 2件: 236, 299
385 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D07546 Bucladesine 1件: 246
386 PDE3A 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction D07961 Flavoxate 1件: 226
387 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00227 Aminophylline 1件: 63
388 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00371 Theophylline 2件: 236, 299
389 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00417 Milrinone 1件: 294
390 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
391 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00718 Flavoxate 1件: 226
392 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01385 Ibudilast 2件: 2, 13
393 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
394 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01712 Theophylline 2件: 236, 299
395 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01896 Cilostazol 3件: 51, 70, 124
396 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02017 Theophylline 2件: 236, 299
397 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02085 Milrinone 1件: 294
398 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D04720 Levosimendan 1件: 2
399 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D05429 Aminophylline 1件: 63
400 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D06103 Theophylline 2件: 236, 299
401 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D06104 Theophylline 2件: 236, 299
402 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D07546 Bucladesine 1件: 246
403 PDE3B 9件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D07961 Flavoxate 1件: 226
404 PPP3CA 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
405 PPP3CA 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
406 PPP3CA 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus 1件: 160
407 PPP3CA 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
408 PPP3CA 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin 1件: 222
409 PPP3CB 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
410 PPP3CB 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
411 PPP3CB 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus 1件: 160
412 PPP3CB 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
413 PPP3CB 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin 1件: 222
414 PPP3CC 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
415 PPP3CC 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
416 PPP3CC 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus 1件: 160
417 PPP3CC 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
418 PPP3CC 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin 1件: 222
419 PPP3R1 24件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
420 PPP3R1 24件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
421 PPP3R1 24件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus 1件: 160
422 PPP3R1 24件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
423 PPP3R1 24件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin 1件: 222
424 PPP3R2 24件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
425 PPP3R2 24件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
426 PPP3R2 24件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus 1件: 160
427 PPP3R2 24件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
428 PPP3R2 24件: MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin 1件: 222
429 PRKCE 10件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Tight junction, Fc gamma R-mediated phagocytosis, Inflammatory mediator regulation of TRP channels, Type II diabetes mellitus, Insulin resistance, Shigellosis, MicroRNAs in cancer D09671 Sotrastaurin 1件: 97
430 MAP2K1 77件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09666 Selumetinib 1件: 34
431 MAP2K1 77件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10175 Trametinib 4件: 2, 34, 279, 280
432 MAP2K1 77件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10405 Cobimetinib 1件: 280
433 MAP2K1 77件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10604 Binimetinib 1件: 34
434 MAP2K2 66件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09666 Selumetinib 1件: 34
435 MAP2K2 66件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10175 Trametinib 4件: 2, 34, 279, 280
436 MAP2K2 66件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10405 Cobimetinib 1件: 280
437 MAP2K2 66件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10604 Binimetinib 1件: 34
438 RAF1 69件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D06272 Sorafenib 2件: 34, 86
439 RAF1 69件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D08524 Sorafenib 2件: 34, 86
440 ROCK1 18件: cGMP-PKG signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, TGF-beta signaling pathway, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer D07941 Fasudil 4件: 2, 5, 7, 51
441 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine 1件: 6
442 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00437 Nifedipine 2件: 50, 81
443 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate 6件: 6, 97, 140, 144, 156, 193
444 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine 4件: 13, 51, 67, 298
445 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00616 Diltiazem 3件: 51, 58, 86
446 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00617 Nicardipine 2件: 70, 86
447 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00619 Verapamil 3件: 96, 140, 167
448 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01173 Cilnidipine 1件: 67
449 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01908 Nilvadipine 1件: 90
450 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02356 Verapamil 3件: 96, 140, 167
451 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine 4件: 13, 51, 67, 298
452 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D03830 Diltiazem 3件: 51, 58, 86
453 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D05442 Perhexiline 2件: 58, 272
454 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
455 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07845 Diltiazem 3件: 51, 58, 86
456 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08270 Nicardipine 2件: 70, 86
457 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08340 Perhexiline 2件: 58, 272
458 CACNA1C 26件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08441 Propiverine 1件: 226
459 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine 1件: 6
460 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00437 Nifedipine 2件: 50, 81
461 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate 6件: 6, 97, 140, 144, 156, 193
462 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine 4件: 13, 51, 67, 298
463 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00616 Diltiazem 3件: 51, 58, 86
464 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00617 Nicardipine 2件: 70, 86
465 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00619 Verapamil 3件: 96, 140, 167
466 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01173 Cilnidipine 1件: 67
467 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01908 Nilvadipine 1件: 90
468 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02356 Verapamil 3件: 96, 140, 167
469 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine 4件: 13, 51, 67, 298
470 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D03830 Diltiazem 3件: 51, 58, 86
471 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D05442 Perhexiline 2件: 58, 272
472 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
473 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07845 Diltiazem 3件: 51, 58, 86
474 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08270 Nicardipine 2件: 70, 86
475 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08340 Perhexiline 2件: 58, 272
476 CACNA1D 25件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08441 Propiverine 1件: 226
477 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine 1件: 6
478 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00437 Nifedipine 2件: 50, 81
479 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate 6件: 6, 97, 140, 144, 156, 193
480 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine 4件: 13, 51, 67, 298
481 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00616 Diltiazem 3件: 51, 58, 86
482 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00617 Nicardipine 2件: 70, 86
483 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00619 Verapamil 3件: 96, 140, 167
484 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01173 Cilnidipine 1件: 67
485 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01908 Nilvadipine 1件: 90
486 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02356 Verapamil 3件: 96, 140, 167
487 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine 4件: 13, 51, 67, 298
488 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D03830 Diltiazem 3件: 51, 58, 86
489 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D05442 Perhexiline 2件: 58, 272
490 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
491 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07845 Diltiazem 3件: 51, 58, 86
492 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08270 Nicardipine 2件: 70, 86
493 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08340 Perhexiline 2件: 58, 272
494 CACNA1F 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08441 Propiverine 1件: 226
495 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine 1件: 6
496 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00437 Nifedipine 2件: 50, 81
497 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate 6件: 6, 97, 140, 144, 156, 193
498 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine 4件: 13, 51, 67, 298
499 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00616 Diltiazem 3件: 51, 58, 86
500 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00617 Nicardipine 2件: 70, 86
501 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00619 Verapamil 3件: 96, 140, 167
502 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01173 Cilnidipine 1件: 67
503 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01908 Nilvadipine 1件: 90
504 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02356 Verapamil 3件: 96, 140, 167
505 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine 4件: 13, 51, 67, 298
506 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D03830 Diltiazem 3件: 51, 58, 86
507 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D05442 Perhexiline 2件: 58, 272
508 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
509 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07845 Diltiazem 3件: 51, 58, 86
510 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08270 Nicardipine 2件: 70, 86
511 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08340 Perhexiline 2件: 58, 272
512 CACNA1S 20件: MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08441 Propiverine 1件: 226
513 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D00302 Dipyridamole 6件: 46, 49, 51, 66, 96, 224
514 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
515 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
516 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02008 Tadalafil 7件: 6, 51, 75, 84, 86, 113, 210
517 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02229 Sildenafil 17件: 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
518 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02731 Vardenafil 3件: 13, 86, 299
519 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D03260 Vardenafil 3件: 13, 86, 299
520 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D08514 Sildenafil 17件: 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
521 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D08668 Vardenafil 3件: 13, 86, 299
522 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D10027 Udenafil 2件: 86, 210
523 ROCK2 19件: cGMP-PKG signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis D07941 Fasudil 4件: 2, 5, 7, 51
524 ROCK2 19件: cGMP-PKG signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis D11815 Belumosudil 1件: 51